Research programme: G-protein coupled receptor modulators - Trevena
Alternative Names: TRV 0109101Latest Information Update: 28 Jun 2022
At a glance
- Originator Trevena
- Class Analgesics; Antidepressants; Antiparkinsonians; Small molecules
- Mechanism of Action G protein-coupled receptor modulators; Opioid delta receptor modulators; Opioid kappa receptor modulators; Opioid mu receptor modulators; Sphingosine 1 phosphate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cachexia; Inflammation; Major depressive disorder; Pain; Parkinson's disease; Peripheral nervous system diseases
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Pain in USA (PO)
- 28 Aug 2021 No recent reports of development identified for preclinical development in Peripheral-nervous-system-diseases in USA
- 03 May 2018 Preclinical development is ongoing for S1P receptors modulators in Pain in USA